The impact of including patients with advanced disease and the role of comprehensive care in the PALM 007 clinical trial, which evaluated the antiviral tecovirimat for treating monkeypox in the Democratic Republic of the Congo.
Jay Varma, MD
Advertisement
Chief Medical Officer at SIGA Technologies.
Articles by Jay Varma, MD
Advertisement
Latest Updated Articles
SIGA Technologies' Trial Results Benefits Mpox Treatment Despite Not Meeting Primary EndpointPublished: August 15th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Practically Expanding AI's role in Infectious Diseases
2
ID Week Brings Education, Networking and Conference Events Altogether Into One Conference
3
Maternal and Infant RSV Immunization Safe, Boosts Antibody Levels Regardless of Sequence
4
ViiV Healthcare Announces 96-Week PASO DOBLE Results Showing Dovato as Effective as Biktarvy in Maintaining Viral Suppression
5
